# Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Mono Products of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers

> **NCT02222428** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 36 (—)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 1744 CL/BI 54903 XX FDC
- **DRUG:** BI 54903 XX
- **DRUG:** BI 1744 CL

## Key facts

- **NCT ID:** NCT02222428
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2009-07
- **Final completion:** —
- **Target enrollment:** 36 (—)
- **Last updated:** 2014-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02222428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02222428, "Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Mono Products of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02222428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*